Marshall Wace
ALIM

Marshall Wace’s Alimera Sciences ALIM Stock Holding History

Marshall Wace’s Portfolio ALIM Stock Details ALIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-85,301
Closed -$333K – 3085
2024
Q1 		$333K Buy
+85,301
New +$325K ﹤0.01% 2077
2021
Q3 		– Sell
-13,086
Closed -$119K – 3522
2021
Q2 		$119K Sell
13,086
-13,429
-51% -$132K ﹤0.01% 2524
2021
Q1 		$255K Buy
+26,515
New +$217K ﹤0.01% 2178

Other funds holding ALIM

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Marshall Wace's ALIM Position: Q2 2024 in Review

Marshall Wace sold out of Alimera Sciences (ALIM) in Q2 2024, closing a stake of 85,301 shares — an estimated $333K sold.

Marshall Wace first reported a position in ALIM in Q1 2021 and held it in 3 quarters. The position peaked at $333K in Q1 2024. 52 funds tracked by Wall St. Rank hold ALIM as of Q2 2024.

  • Marshall Wace reported no remaining Alimera Sciences position as of Q2 2024 after selling out during the quarter.
  • Marshall Wace sold 85,301 Alimera Sciences shares in Q2 2024, an estimated $333K.
  • Marshall Wace first reported a position in Alimera Sciences in Q1 2021 and held it in 3 quarters.
  • Marshall Wace's Alimera Sciences position peaked at $333K in Q1 2024.
  • 52 funds tracked by Wall St. Rank held Alimera Sciences as of Q2 2024.

Based on Marshall Wace's 13F filing for Q2 2024, filed 14 Aug 2024.